• Paysign discussed Q1 2026 results on a May 12 earnings call attended by Co-Founder, Chairman and CEO Mark Newcomer, CFO Jeff Baker, President of Patient Affordability Matt Turner, Chief Payments Officer Matt Lanford, Lake Street’s Jacob Stephan, Barrington’s Gary Prestopino, D.A. Davidson’s Peter Heckmann, Ladenburg Thalmann’s Jon Hickman.
• Revenue rose 50.8% to USD 28 million; net income increased 110% to USD 5.4 million; adjusted EBITDA climbed 113.4% to USD 10.6 million; operating margin widened to 23.8% from 13.4%.
• Patient affordability revenue jumped 81.9% to USD 15.7 million on roughly 49% higher processed claims; active programs ended quarter at 135, rose to 141 as of call, forecast to reach 147-150 by end of Q2.
• Plasma revenue grew 24.9% to USD 11.7 million; centers ended quarter at 573, expected to fall to 555-560 in Q2 after 19 closures, with donor migration expected to offset volume impact.
• Full-year outlook maintained at USD 106.5 million to USD 110.5 million revenue, USD 13 million to USD 16 million net income, USD 30 million to USD 33 million adjusted EBITDA; management flagged ongoing FDA discussions on SaaS/app with no revenue contribution yet, cash at USD 20.5 million with zero bank debt, no share repurchases in quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.